Finland· FI-REL-REL41835
Scenesse
A afamelanotide product containing afamelanotide acetate, registered in Finland by Clinuvel Europe Limited. The same ATC class is registered in 10 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Afamelanotide is registered in 10 of 19 countries.
Countries holding a registration under ATC D02BB02 (afamelanotide), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 6 of them publish a price we can compare per daily dose
Afamelanotide · ATC D02BB02
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Afamelanotide acetate
- Manufacturer
- Clinuvel Europe Limited
- Country
- Finland (FI)
- ATC code
- D02BB02
- ATC class
- Afamelanotide
- Defined daily dose
- 0.00822 DE, Implantat
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Afamelanotide in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumScenesse 16 mgClinuvel Europe
- CzechiaSCENESSECLINUVEL EUROPE LIMITED, Dublin
- SpainSCENESSE 16 MG IMPLANTEClinuvel (Uk) Limited
- United KingdomScenesse 16mg implantClinuvel (UK) Ltd
- IrelandSCENESSE 16 mg implantClinuvel Europe Limited
- IcelandSCENESSEClinuvel Europe Limited
- NetherlandsSCENESSE 16 mg, implantaatClinuvel Europe Limited
- PolandScenesseCLINUVEL EUROPE LIMITED
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Scenesse
- Liechtenstein · Scenesse
- Norway · Scenesse
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5847ab7d-500f-409b-8237-32d6ed3e511a GET /v1/drugs/5847ab7d-500f-409b-8237-32d6ed3e511a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "implantaatti",
"route": "Ihon alle",
"ddd_unit": null,
"strength": "16 mg",
"atc_label": "afamelanotidi",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/14/969/001",
"fimea_rel_id": "REL41835",
"authorised_at": "2014-12-22"
}See everything about afamelanotide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.